A study of response to lipid lowering therapy in non-diabetic patients with dyslipidemia at tertiary health care center

 

Raju Talawar¹, Darshna Makwana^2*

 

¹Assistant Professor, Department of General Medicine, J.N.M.C. Nehru Nagar, Belagavi, Karnataka-590010, INDIA.

²Assistant Professor, Department of General Medicine, B.J.M.C. Asarwa, Ahmedabad, Gujarat, INDIA.

Email: drrajutalawar@gmail.com

REFERENCES

1. Donnan, G. A., Fisher, M., Macleod, M., Davis, S.M. Stroke. Lancet, 2008, 371, 1612-1623. doi:10.1016/S0140-6736(08)60694-7
2. Dirnagl, U., Iadecola, C., Moskowitz, M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci., 1999, 22, 391-397. doi:10.1016/S0166-2236(99)01401-0
3. Endo, A., Kuroda, M., Tsujita, Y. ML-236A, ML-236B, and ML- 236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot., 1976, 29, 1346-1348. http://dx.doi.org/ 10.7164/antibiotics.29.1346
4. Anderson, T.J., Meredith, I.T., Yeung, A.C., Frei, B., Selwyn, A.P., Ganz, P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med., 1995, 332, 488-493. DOI: 10.1056/NEJM199502233320802
5. Obi, C., Wysokinski, W., Karnicki, K., Owen, W.G., McBane, R.D. 2nd. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 1271-1276. doi: 10.1161/ ATVBAHA.109.190884
6. Rasmussen, L.M., Hansen, P.R., Nabipour, M.T., Olesen, P., Kristiansen, M.T., Ledet, T. Diverse effects of inhibition of 3- hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J., 2001, 360, 363-370. PMID: 11716764
7. Wagner, A.H., Kohler, T., Ruckschloss, U., Just, I., Hacker, M. Improvement of nitric oxide-dependent vasodilatation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 61-69. doi: 10.1161/01.ATV.20.1.61
8. Ward, S., Lloyd, J.M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., Payne, A. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol., Assess., 2007, 11, 1-160. iii-iv. http://dx.doi.org/10.1108/cgij.2007. 24812dae.001
9. Kawashima, S., Yamashita, T., Miwa, Y., Ozaki, M., Namiki, M., Hirase, T., Inoue, N., Hirata, K., Yokoyama, M. HMG-CoAreductase inhibitor has protective effects against stroke events in spontaneously hypertensive rats. Stroke, 2003, 34, 157-163. doi: 10.1161/01.STR.0000048213.18751.52
10. Prinz, V., Laufs, U., Gertz, K., Kronenberg, G., Balkaya, M., Leithner, C., Lindauer, U., Endres, M. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke, 2008, 39, 433-438. doi: 10.1161/STROKEAHA.107.492470
11. Sironi, L., Cimino, M., Guerrini, U., Calvio, A.M., Lodetti, B., Asdente, M., Balduini, W., Paoletti, R., Tremoli, E. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscl. Throm. Vas., 2003, 23, 322-327. doi: 10.1161/01.ATV.0000044458.23905.3B
12. White, H.D., Simes, R.J., Anderson, N.E., Hankey, G.J., Watson, J.D., Hunt, D., Colquhoun, D.M., Glasziou, P., MacMahon, S., Kirby, A.C., West, M.J., Tonkin, A.M. Pravastatin therapy and the risk of stroke. N. Engl. J. Med., 2000, 343, 317-326. DOI: 10.1056/ NEJM200012213432513
13. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., Ford, I., Gaw, A., Hyland, M., Jukema, J.W., Kamper, A.M., Macfarlane, P.W., Meinders, A.E., Norrie, J., Packard, C.J., Perry, I.J., Stott, D.J., Sweeney, B.J., Twomey, C., Westendorp, R.G., PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial. Lancet, 2002, 360, 1623-1630. doi:10.1016/S0140-6736(02)11600-X
14. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova, B., Emberson, J., Blackwel, l L., Keech, A., Simes, J., Barnes, E.H., Voysey, M., Gray, A., Collins, R., Baigent, C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012, 380, 581-590. doi: 10.1016/ S0140-6736(12)60367-5.
15. Topol, E.J. Intensive statin therapy--a sea change in cardiovascular prevention. N. Engl. J. Med, 2004, 350, 1562-1564. DOI: 10.1056/ NEJMe048061
16. No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet, 1994, 344, 1383-1389. doi:10.1016/ S0140-6736(94)90566-5
17. Vauthey C, de Freitas GR, van Melle G, Devuyst G andBogousslavsky J. (2000) Better outcome after stroke with higher serum cholesterol levels. Neurology 54: 1944−1949.
18. Dyker AG, Weir CJ and Kennedy RL. (1997) Influence of cholesterol on survival after stroke. Retrospective study. BMJ 314: 1584−1588.
19. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteborg, Sweden. Stroke 1990; 21:223–229.
20. Njolstal I, Arnesan E, Lund – Laven PG. Body height, cardiovascular risk factors and risk of stroke in middle aged men and women A 14 year follow up of the Finnmark Study. Circulation 1996; 94: 2877-2882.
21. Garg R.K, Gaur SPS, Kar A.M, Srimal RC. Platelet functions and lipid profile in hemorrhagic and thrombotic stroke. JAPI 1994; 42(4): 294-297.
22. Hachinski V, Graffagnino C, Beaudry M et al. Lipids and stroke a paradox revealed. Arch Neurol 1996 Apr; 53(4): 303-8.